- Previous Close
11,190.00 - Open
11,040.00 - Bid 11,130.00 x --
- Ask 11,160.00 x --
- Day's Range
11,040.00 - 11,290.00 - 52 Week Range
10,960.00 - 20,300.00 - Volume
8,309 - Avg. Volume
17,855 - Market Cap (intraday)
154.977B - Beta (5Y Monthly) 0.70
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date May 1, 2025 - May 5, 2025
- Forward Dividend & Yield 200.00 (1.78%)
- Ex-Dividend Date Feb 27, 2025
- 1y Target Est
--
HANDOK Inc. operates as a pharmaceutical company. The company provides ETC and OTC drugs; and medical devices and research products, including blood pressure monitors, cholesterol monitoring systems, insulin pumps, self monitoring system of blood glucose, and blood glucose monitoring system. It focuses on various therapeutic areas, such as oncology, diabetes and metabolic disorders, CNS, orphan diseases, eye disorders, and other disease areas. The company also offers healthcare products comprising food supplements under the NatureSet brand; food and beverages; and medical nutrition products. The company was formerly known as Handok Pharmaceuticals Co., Ltd and changed its name to Handok Inc. in July 2013. Handok Inc. was founded in 1954 and is based in Seoul, South Korea.
www.handok.co.kr--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 002390.KS
View MorePerformance Overview: 002390.KS
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 002390.KS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 002390.KS
View MoreValuation Measures
Market Cap
154.98B
Enterprise Value
472.33B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.31
Price/Book (mrq)
0.54
Enterprise Value/Revenue
0.93
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-10.36%
Return on Assets (ttm)
-0.21%
Return on Equity (ttm)
-16.73%
Revenue (ttm)
507.36B
Net Income Avi to Common (ttm)
-52.56B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
56.04B
Total Debt/Equity (mrq)
129.18%
Levered Free Cash Flow (ttm)
-19.01B